Global Asthma Therapeutics Market by Drug Class (Inhaled Corticosteroids, Beta-agonists, Leukotriene Modifiers, Biologics, Combination Drugs), by Route of Administration (Oral, Inhalation, Injection), by End-Use Industry (Hospitals and Clinics, Home Care, Ambulatory Care Centers); Insights & Forecast (2024 ? 2030)

As per Intent Market Research, the Asthma Therapeutics Market was valued at USD 20.9 Billion in 2024-e and will surpass USD 39.4 Billion by 2030; growing at a CAGR of 11.2% during 2025 - 2030.

The asthma therapeutics market is witnessing substantial growth as the global prevalence of asthma continues to rise. Asthma is a chronic respiratory condition that requires consistent management through medication to alleviate symptoms and prevent exacerbations. The market for asthma therapeutics includes a wide range of drug classes, such as corticosteroids, beta-agonists, leukotriene modifiers, biologics, and combination drugs, that work to control inflammation, relax airway muscles, and prevent future asthma attacks. With the increasing focus on personalized medicine and advanced biologics, the market is evolving to offer more targeted and effective treatments for asthma patients. The expansion of healthcare access and advancements in drug delivery technologies are further propelling the market's growth, especially as patients seek treatments that offer better control and fewer side effects.

Inhaled Corticosteroids (ICS) Are Largest Drug Class Owing to Proven Efficacy

Inhaled corticosteroids (ICS) represent the largest drug class in the asthma therapeutics market, owing to their proven efficacy in controlling asthma symptoms and preventing exacerbations. ICS medications work by reducing inflammation in the airways, which is a primary cause of asthma symptoms. These drugs are considered the first-line therapy for long-term asthma management, particularly for individuals with moderate to severe asthma.

ICS drugs are delivered directly to the lungs through inhalers, ensuring that the medication acts directly on the inflamed areas, reducing systemic side effects. The effectiveness of ICS in improving lung function and preventing acute asthma attacks makes them the cornerstone of asthma treatment regimens. As asthma diagnoses continue to rise globally, the demand for ICS remains strong, cementing its position as the largest drug class in the asthma therapeutics market.

Inhalation Route of Administration Is Fastest Growing Due to Enhanced Drug Delivery

The inhalation route of administration is the fastest-growing segment in the asthma therapeutics market, driven by advancements in inhaler technologies and the increasing preference for targeted drug delivery. Inhaled medications, such as ICS and beta-agonists, offer several advantages over oral and injectable forms, including faster onset of action and direct delivery to the lungs, where the medication is most needed.

Innovations in inhalation devices, such as dry powder inhalers (DPIs) and metered-dose inhalers (MDIs), have improved the ease of use and efficiency of delivering asthma drugs. The growing focus on patient compliance and self-management of asthma has further fueled the adoption of inhaled therapies. Inhalation remains the preferred method for delivering asthma drugs, especially for managing chronic symptoms and preventing attacks, making it the fastest-growing route of administration in the market.

Hospitals and Clinics Segment Is Largest End-Use Industry Due to Acute and Ongoing Care

The hospitals and clinics segment is the largest end-use industry in the asthma therapeutics market, due to the critical role these healthcare settings play in the diagnosis, treatment, and management of asthma. Hospitals and clinics provide a wide range of asthma therapeutics, from emergency interventions for acute attacks to ongoing management of chronic symptoms.

Asthma patients often require regular visits to hospitals and clinics, especially when dealing with severe cases or exacerbations. Healthcare professionals in these settings are equipped to administer a variety of asthma therapies, including inhaled medications, biologics, and combination treatments, ensuring effective and comprehensive care. As asthma is a long-term condition that necessitates continuous monitoring and treatment, hospitals and clinics remain the leading end-use industry for asthma therapeutics.

North America Is Largest Region Due to High Asthma Prevalence and Advanced Healthcare

North America is the largest region in the asthma therapeutics market, driven by high asthma prevalence, access to advanced healthcare, and a large population of asthma patients. The United States, in particular, has a significant asthma burden, with millions of individuals suffering from the condition. The region’s well-developed healthcare infrastructure ensures that patients have access to the latest asthma therapies, including biologics, inhaled corticosteroids, and combination treatments.

Additionally, North America has a high level of awareness about asthma management and the availability of medications, contributing to increased demand for effective asthma therapeutics. With ongoing innovations in asthma drug formulations and delivery methods, North America is expected to maintain its leadership position in the global market.

Competitive Landscape and Key Players

The asthma therapeutics market is competitive, with key players such as GlaxoSmithKline, AstraZeneca, Merck, Novartis, and Boehringer Ingelheim leading the development and marketing of asthma drugs. These companies offer a broad range of asthma therapeutics, including inhaled corticosteroids, biologics, beta-agonists, and combination drugs, that cater to diverse patient needs.

The competitive landscape is characterized by the continuous development of new therapies, including biologics and personalized medicine options, that target specific asthma triggers and provide long-lasting relief. Strategic collaborations, acquisitions, and ongoing research and development are common strategies used by market leaders to expand their product offerings and strengthen their position. As asthma care evolves, the market is expected to witness further advancements in drug delivery systems, enhancing the effectiveness of asthma therapeutics and improving patient outcomes.

Recent Developments:

• AstraZeneca received FDA approval for its new biologic asthma therapy, targeting severe eosinophilic asthma for better symptom control.
• Teva Pharmaceuticals launched a new combination inhaler to improve asthma management by combining a corticosteroid and bronchodilator in one device.
• Regeneron Pharmaceuticals announced a collaboration with Sanofi for the joint development of a novel biologic for asthma treatment.
• GlaxoSmithKline introduced a long-acting beta-agonist inhaler designed for daily use to manage chronic asthma symptoms in adults and children.
• Boehringer Ingelheim expanded its portfolio by releasing an innovative leukotriene modifier for better asthma control in children and adults.

List of Leading Companies:

• GlaxoSmithKline Plc
• Novartis International AG
• Boehringer Ingelheim GmbH
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Pfizer Inc.
• Mylan N.V.
• Horizon Therapeutics plc
• Chiesi Farmaceutici S.p.A.
• Bristol-Myers Squibb Company
• Amgen Inc.

Report Scope: